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Background: The effect of oral polio vaccine administered already at birth (OPV0) on child survival was not
examined before being recommended in 1985. Observational data suggested that OPV0 was harmful for boys, and
trials have shown that neonatal vitamin A supplementation (NVAS) at birth may be beneficial for boys. We set out
to test this research question in a randomised trial.
Methods: The trial was carried out at the Bandim Health Project, Guinea-Bissau. We planned to enrol 900 low-birth
weight (LBW) boys in a randomised trial to investigate whether NVAS instead of OPV0 could lower infant mortality
for LBW boys. At birth, the children were randomised to OPV (usual treatment) or VAS (intervention treatment) and
followed for 6 months for growth and 12 months for survival. Hazard Ratios (HR) for mortality were calculated using
Cox regression. We compared the individual anthropometry measurements to the 2006 WHO growth reference. We
compared differences in z-scores by linear regression. Relative risks (RR) of being stunted or underweight were
calculated in Poisson regression models with robust standard errors.
Results: In the rainy season we detected a cluster of deaths in the VAS group and the trial was halted immediately
with 232 boys enrolled. The VAS group had significantly higher mortality than the OPV0 group in the rainy season
(HR: 9.91 (1.23 – 80)). All deaths had had contact with the neonatal nursery; of seven VAS boys enrolled during one
week in September, six died within two months of age, whereas only one died among the six boys receiving OPV
(p = 0.05). Growth (weight and arm-circumference) in the VAS group was significantly worse until age 3 months.
Conclusion: VAS at birth instead of OPV was not beneficial for the LBW boys in this study. With the premature
closure of the trial it was not possible to answer the research question. However, the results of this study call for
extra caution when testing the effect of NVAS in the future.
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In low income countries a policy of providing neonatal
vitamin A supplementation (VAS) is currently under de-
bate. Four randomised trials from Africa and one from
Nepal have shown no overall effect on mortality of neo-
natal VAS [1-5]. Three trials from South East Asia have
reported a beneficial effect [6-8]. Several of the trials
suggested that while VAS conferred few benefits or even
a negative effect for girls, it had a positive effect in boys
[1,2,6,8]. From 1985 WHO recommended a dose of oral
polio vaccine at birth (OPV0) in addition to the three
doses at 6, 10 and 14 weeks of age (OPV1-3). This pol-
icy was introduced to improve coverage and immune
responses [9-13]. The effect of OPV at birth on overall
child mortality was never studied.
The Bandim Health Project (BHP) has worked in Guinea
Bissau since 1978 and has examined non-specific and
sex-differential effects on mortality of childhood inter-
ventions. From 2002–2004 when BHP was conducting
a trial of neonatal VAS to normal birth weight children,
OPV was lacking for several periods [14] and some of
the enrolled children did not get the recommended
OPV0. Surprisingly, boys who did not receive OPV0 only
had a third of the mortality of boys who got the vaccine.
The tendency was slightly opposite in girls, resulting in
a highly significant interaction between OPV at birth
and sex (p = 0.006). We also studied the effect of OPV0
on the immune response to BCG vaccine; both sexes had
a dampened immune response to BCG if they received
OPV together with BCG [15].
Based on these results we hypothesised that newborn
LBW boys might benefit from receiving VAS at birth
instead of OPV0, and we conducted a randomised trial to
test that hypothesis. As the previous studies suggested a
harmful effect of VAS in girls [2], only boys were rando-
mised to receive VAS or OPV0. Girls were enrolled in an-
other trial. The trial proceeded as planned from February
2008 until November 2008 when the study supervisor
noted a bulk of death reports. Seven boys born between
28 August and 16 September 2008 had died before the
2 months visit. Among the seven deaths six had received
VAS. This looked like a cluster and the PI decided to halt
the trial to examine possible causes and avoid continuing
an intervention which potentially had negative effects.
Methods
Setting
The BHP runs a Health and Demographic Surveillance
System (HDSS) in six districts of Bissau, the capital of
Guinea-Bissau. Since 2002 the BHP has followed a co-
hort of LBW children from the whole capital. All new-
born children weighing less than 2.5 kg at discharge
from the maternity ward of the national hospital (NH)
are invited to participate. At the time of the trial, 13%of the children born at the NH were LBW. The children
and their mothers are driven home from the hospital.
A map is drawn describing the localisation of their
houses, GPS coordinates are recorded, and a photo of
the house and the mother is taken to ensure that the
team will be able to localise the child at subsequent
visits. When a child moves, a relative or a neighbour
takes the team to the new address. In this way very few
children are lost to follow up. LBW children living in-
side the BHP study area who are born at home are re-
cruited when they come for their first vaccinations at
one of the three health centres in the study area. In
Guinea-Bissau LBW children do not receive BCG at
birth, but are told to come back when they have gained
weight, and they typically get BCG together with the
DTP and OPV scheduled at 6 weeks of age.
The neonatal nursery offers a very basic care level
with possibility of phototherapy and intravenous infu-
sion. Intubation and oxygen therapy was not possible
at the time the trial was conducted. Admitted children
did often share the available incubators. The service of
the neonatal nursery is free, and children of all gestational
ages are admitted. There is no possibility of transmission
to a higher specialised unit.
Enrolment
The study was initiated 20 February 2008. LBW children
identified at the hospital were examined by a doctor or a
trained nurse who also assessed maturity using Ballard
score [16]. Anthropometric measurements were obtained
and the child was examined. Eligible were boys with a
weight below 2.5 kg. Exclusion criteria were major malfor-
mations, female sex, and weight at enrolment of ≥ 2500 g.
Children who had already received BCG and children with
clinical signs of vitamin A deficiency were also excluded,
as were children that were too sick to be discharged by
local standards. These children were referred for treat-
ment. There was no age criterion, as all children weigh-
ing less than 2500 g and coming for their first vaccines
were eligible. The oldest child enrolled was 64 days old,
and the age distribution is described in Table 1. The
mothers were informed of the study in the local lan-
guage, Creole, and got a written explanation of the study
in the official language, Portuguese. Oral and written
consent was obtained. The mother signed the enrolment
form if she could write, if not she put a fingerprint, and an
independent observer signed the form. Provided consent,
the mother drew a lot from a bag. The lot decided which
treatment, VAS or OPV, her son would receive at enrol-
ment. Randomisation was done in blocks of 24. The
bags were prepared by the study supervisor; each bag
contained 24 stapled lots in separate opaque envelopes.
Twins were allocated the same treatment to prevent po-
tential confusion regarding who had been vaccinated
Table 1 Baseline characteristics of the two randomisation
groups
VAS at birth OPV at birth
(N = 116) (N = 116)
Enrolled in rainy season, n (%) 70 (60) 71 (61)
Enrolled at NH, n (%) 102 (88) 99 (85)
Living inside study area, n (%) 34 (29) 36 (31)
Twin, n (%) 26 (22) 24 (21)
Admission to neonatal nursery, n (%) 29 (25) 30 (26)
Age at inclusion, days (10–90 centiles) 2.5 (1–10) 2 (1–10)
Birth weight, kg (10–90 centiles) 2.21 (1.66-2.45) 2.22 (1.66-2.46)
Ballard score* (10–90 centiles) 36 (27–43) 36 (27–43)
Median maternal age, years
(10–90 centiles)
23 (16–29) 22 (17–32)
Maternal schooling, n (%)
None 40 (34) 38 (33)
<6 years 19 (16) 26 (22)
≥6 years 57 (49) 52 (45)
Electricity available, n (%)
Yes 27 (23) 35 (30)
No 88 (76) 80 (69)
Unknown 1 (1) 1 (1)
Parity, n (%)
1 62 (53) 57 (49)
2-3 30 (26) 34 (29)
>3 23 (20) 24 (21)
Unknown 1 (1) 1 (1)
Maternal MUAC, mm (10–90 centiles) 232 (208–276) 238 (208–284)
Abbreviations: NH National hospital; MUAC Mid upper arm circumference.
*Only available for children enrolled at the national hospital.
Figure 1 Trial profile.
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their child to a health centre at 6 weeks of age to get
BCG, OPV, and DTP. At every home visit the assistants
checked the children’s vaccination cards and pointed
out missing vaccines for the mothers to ensure that all
children got OPV. Enrolment staff did not take part in
the follow-up of the children.
Interventions
Vitamin A was given as a 0.5 ml oral supplement which
was slowly released into the mouth of the child with a
sterile syringe by a nurse. The supplement came in
dark glass bottles that were prepared at Skanderborg
Pharmacy, Denmark, and contained 20 doses of 25000 IU
vitamin A as retinyl palmitate and 10 IU vitamin E per
0.5 ml oil. The bottles were kept at 2-8°C. Trivalent
OPV was supplied through the national immunisation
programme and administered orally. There was no
blinding.Outcomes
Primary outcome: infant mortality
The LBW children were visited within the first 3 days
after enrolment, and children living inside the study area
were visited on day 1–3 after enrolment to check for ad-
verse events. All children who had not died, moved or
were travelling were visited at 2, 6, and 12 months of
age (Figure 1). The children living inside the BHP study
area were furthermore followed by the HDSS. If the
child moved outside Bissau or was absent at the visit,
relatives or neighbours were asked if the child was still
alive and how soon they would be told if the child died.
Children travelling at 12 months were visited again at
15–18 months of age. When a death was registered, the
assistant asked for the child’s health card. A verbal aut-
opsy was conducted around three months after the
death by a trained assistant. A local doctor read the aut-
opsy and proposed a diagnosis. The cause of death in
broad categories was determined later after reading the
verbal autopsy and taking into account the local doctor’s
diagnosis and possible hospital records.
We collected information on temperature, respiratory
frequency, weight gain and a few other variables in the
first three days after enrolment to be able to detect pos-
sible adverse effects of the intervention (which we did
not find); however, we did not collect information on
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enrolled in the trial.
Secondary outcome: growth
A subgroup of children was visited biweekly for the first
3 months and at 4, 5, and 6 months of age by an anthro-
pometry team measuring weight, length, and arm and
head circumference. This sub study was initiated 10 April
2008 and continued enrolling children until the main trial
was stopped at 18 November 2008. Measurements were
made by two trained field assistants who visited the home
of the child. The length of the child was measured supine
using a measuring board (Seca Model 416). The weight of
the undressed child was measured to the nearest 20 g
using an electronic scale (Seca Model 835/336). Middle
upper arm circumference (MUAC) and head circumference
were measured using a TALC insertion tape. Children who
were temporarily absent were visited later the same or the
following day, whereas children travelling were only visited
at the following round. Children who moved were localised
as described above.
Sample size considerations
We expected to enrol 900 boys in three years. With a
mortality of 15% between enrolment and 12 months of
age, we had 80% power to detect a 40% reduction in
mortality for boys with a confidence level of 95%. With a
sample size of 300 boys in the growth study, we should
be able to detect a weight difference of 150 g in favor of
the proposed versus the current policy with a power of
80% and a one-sided alpha of 0.05.
Special investigations initiated after the identification of
the cluster
Due to the cluster of deaths described in this paper, one
of the authors (NL) supervised the verbal autopsies of
the children. In November and December 2008, after the
cluster was identified, we took 20 throat swabs from
children currently treated at the neonatal nursery to
search for viruses. The sample was collected with a cotton
swab from the back of the child’s throat and placed in an
Eppendorff tube containing 1 mL of alcohol. The tubes
were stored at room temperature until analysis at Statens
Serum Institut, Denmark. The samples were examined for
Influenza A and B, Respiratory Syncytial Virus, Human
Metapneumovirus, Parainfluenza, Adeno, Corona, Rhino,
Entero, and Parecho viruses using PCR on a MagNaPure
system. However, when the samples were collected there
was no longer a mortality problem at the nursery and
nothing was found in the throat swabs. Likewise we con-
ducted immunological examinations of cytokine responses
among children recruited in October and November. Few
children were included and the cluster of deaths had
passed. Hence, the results were unrevealing.Statistical methods
Statistical analysis was performed using Stata 11.2 soft-
ware (Stata Corporation, College Station, TX). Baseline
characteristics of children in the VAS group vs. children
in the OPV group were compared using logistic or linear
regression.
We used Cox regression to calculate Hazard Ratios
(HR) for mortality with 95% Confidence Intervals (CI).
Robust standard errors were used to account for inter-
dependency of outcome between twins. Age was used as
the underlying time and was thus inherently controlled for
in the mortality analyses. Test for proportionality of hazard
rates were computed using Schoenfeldt residuals and by
visual inspection of the cumulative risk curves. Cumulative
mortality curves were drawn using the Kaplan-Meier
method. We tested whether there were differences in
the age at death in a linear regression model on the
log-transformed age.
We tested interactions between baseline characteristics,
season of enrolment (rainy season June to November, dry
season December to May), and admission to neonatal nur-
sery before enrolment by Wald test statistics. We analysed
effect modification by investigating the homogeneity of
the effect of the intervention in the different categories of
the suspected modifier, also by Wald test statistics. Effect
modifiers considered were age at and place of enrolment,
place of residence, birth weight, head circumference,
MUAC, and maternal MUAC, age, parity, schooling, and
socioeconomic status.
We compared the individual anthropometry measure-
ments to the 2006 WHO growth reference [17]. Z-scores
for length-for-age, weight-for-age, head circumference for
age, and mid-upper-arm-circumference (MUAC)-for-age
(only available for children aged 12 weeks or more) were
derived. Children were classified as stunted (length-for-age
z-score≤−2) and underweight (weight-for-age z-score≤−2)
at all time points. We compared differences in z-scores by
linear regression. For variables that were not normally dis-
tributed, geometric mean ratios (GMRs) were calculated
from the log-transformed variable. Differences in growth be-
tween baseline and 4 weeks visits were compared using lin-
ear regression. We calculated relative risks (RR) of being
stunted or underweight in Poisson regression models with
robust standard errors [18]. Possible interaction with season
of inclusion was explored.
Ethics statement
There have been no cases of poliomyelitis in Guinea-Bissau
for at least a decade. As a “natural experiment” had
worryingly shown that boys who had not received OPV
at birth had significantly lower mortality than boys
who had received OPV at birth [14], and as OPV is also
provided at 6, 10 and 14 weeks of age and during na-
tional immunisation days, we found it ethically justified
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had been randomised to vitamin A. The protocol was
approved by the Guinean Ministry of Health’s Research
Coordination Committee, and the Danish Central Ethics
Committee gave its consultative approval. The trial was reg-
istered at www.clinicaltrials.gov, identifier NCT00625482.
Results
From 20 February 2008 to the trial was halted on 18
November 2008 a total of 237 boys were invited to par-
ticipate. Two mothers refused participation, one child
received vaccines before randomisation, and one child
turned out not to be eligible due to a malformation.
One child in the VAS group had weighed 2300 g at birth
but had gained weight and weighed 2500 g at inclusion
and was excluded from analysis (Figure 1). Hence, we
ended up with 232 boys; 116 in the OPV group and 116 in
the VAS group. As shown in Figure 1, at the 12 months
visits, three children in each group had moved; however,
only two of the children, one in each group, could not be
confirmed alive. All travelling children were confirmed
alive by relatives or neighbours.
Baseline characteristics of the two intervention groups
are shown in Table 1. The medical examination made be-
fore enrolment showed no difference in heart frequency,
respiratory frequency, or temperature between the cluster
children and the non-cluster children enrolled from the
neonatal nursery or from the maternity ward. Breastfeed-
ing was initiated in all children. At the 2 months visit, all
visited children were breastfed. At the 6 months visit, 4
children in the OPV group and 2 in the VAS group were
not breastfed any more. Of these, one child (OPV) died
before 12 months of age. At the 12 months visit, another
4 children had been weaned (1 OPV, 3 VAS).
Mortality cluster
When several death forms were brought back by the an-
thropometric team and the team conducting the 2-months
visits in October-November 2008, we compiled the
mortality statistics shown in Table 2. Season was moni-
tored because previous analyses had shown that
though the overall effect of VAS appeared to be benefi-
cial for boys, there might not be a beneficial effect in
the rainy season. This was strongly supported by the
incoming reports; there was 10-fold increased mortal-
ity among boys receiving VAS in the rainy season and a
clear inversion of the pattern between dry and rainy
season (Table 2). Based on these data we decided to
temporarily halt the enrolment of LBW boys on 18
November 2008. As shown in Figure 2a, mortality in
the group receiving VAS was 7 fold higher in the first
month of life (HR = 7.20 (95% Confidence Interval
(CI): 0.89 – 58.5)) and 3 fold higher at 2 months of age
(HR = 2.85 (0.91 – 8.93)).Subsequent examinations showed that the children who
died had not received the same bottle of VAS and com-
mon contamination was therefore unlikely. However, the
examination revealed that most of the children who died
had been in the neonatal nursery (Table 3). Of the 14 boys
admitted to the neonatal nursery during September 2008,
two died before being discharged; of the 12 boys being dis-
charged and enrolled in the present trial, six received VAS
of whom five died whereas six received OPV of whom one
died within two months of age (p = 0.05). One VAS boy
enrolled in September who also died within the first
2 months of life had not himself been admitted to the
neonatal nursery, but his twin had. These seven boys were
between 9 and 43 days old when they died; the median
age was 18 days. Among the additional children enrolled
at all enrolment sites in October and November before we
halted the study, there were no deaths (Table 3).
Main outcome: infant mortality
Followed to 12 months of age the mortality rate was 11.4
deaths per 100 person-years, somewhat lower than the
anticipated 15/100 (Figure 2a-c). Fourteen VAS boys and
10 OPV boys died resulting in a HR of 1.46 (0.65 – 3.29)
(Table 2). The estimates did not change if children who
moved or were travelling were censored at the day they left.
At 2 and 6 months of age the HR for VAS vs. OPV were
2.85 (0.91 – 8.93) and 1.69 (0.70 – 4.09), respectively.
All deaths among children included in the rainy season
occurred before two months of age and VAS boys were
therefore overall younger than OPV boys when they died
(median age at death of 28 days in VAS boys and 82 days
in OPV boys, p = 0.04).
The number of very low birth weight babies (VLBW,
birth weight < 1500 g) was 7 (6%) in each group. Two of
the VLBW babies in the OPV group died during follow up,
one of them was enrolled at the neonatal nursery during
September 2008 (the cluster period). Another VLBW baby
in the OPV group was also enrolled from the neonatal nur-
sery during this period but survived. Three VLBW babies
in the VAS group died during follow up, one of them was
enrolled from the neonatal nursery in the cluster period.
None of the other VLBW babies in the VAS group were
enrolled during the cluster period.
Causes of death
Of the seven dead children enrolled in the cluster period,
four (all VAS) died from respiratory diseases (Table 4).
One child (OPV) died from kernicterus, and the cause of
death could not be established in two children (VAS).
Secondary outcomes: growth
Eighty-six children from the OPV group and 87 from the
VAS group were enrolled in the anthropometry sub study;
82 and 77 children, respectively, had at least one visit.
Table 2 The effect of VAS/OPV at birth on infant mortality overall and by season of enrolment
Censored at 18 November 2008 With full follow up time
VAS OPV VAS vs. OPV VAS OPV VAS vs. OPV
MR MR HR (95% CI) MR MR HR (95% CI)
(Deaths/pyrs) (Deaths/pyrs) (Deaths/pyrs) (Deaths/pyrs)
All 35.1 21.2 1.66 (0.68 – 4.02) 13.6 9.3 1.46 (0.65 - 3.29)
13/37 8/37 (14/103) (10/108)
By season
Dry 15.8 28.9 0.54 (0.16 - 1.84) 11.9 23.3 0.53 (0.18 - 1.55)
4/25 7/24 (5/42) (9/39)
Rainy 77.1 7.4 10.0 (1.24 – 80.5) 14.9 1.4 9.91 (1.23 - 79.8)
9/12 1/14 (9/61) (1/69)
P for interaction 0.02 0.02
MR per 100 years of follow up.
Abbreviations: Pyrs person years of follow up.
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at each visit. Of the 173 children enrolled in the an-
thropometry study, nine VAS and two OPV boys died
before the last anthropometry visit at 6 months after
enrolment, corresponding to a relative risk (RR) of loss
to follow up due to death for VAS vs. OPV of 4.44
(0.99 – 20.08).
In the subgroup followed for growth, more children in
the VAS group were stunted at baseline. We therefore
adjusted length measures at the following visits for being
stunted at baseline in analyses where adjustment chan-
ged the estimate by more than 10%. Two weeks after en-
rolment VAS children were significantly lighter and had
a lower weight-for-age z-score and MUAC than OPV
children. These differences were also found at the 4, 6,
10, and 12 week visits (data only shown for the 4 weeks
visit, Table 5). There were no differences in length and
head circumference between the two groups at any visit
when length analyses were controlled for being stunted
at baseline. At 6 months VAS children were more often
underweight than OPV children (Table 5). Because of
the imbalance of stunted children between the two
groups, we studied growth between baseline and the
4 weeks visit. It turned out that even though stunted
children, regardless of randomisation group, experienced
significantly better linear growth than non-stunted chil-
dren between baseline and 4 weeks, probably reflecting a
catch up growth, VAS children had a significantly poorer
linear growth (Difference adjusted for being stunted at
baseline = −1.02 (−1.66; −0.38)) between baseline and
4 weeks). There was no interaction between growth and
season (data not shown).
Discussion
Principal findings
A cluster of deaths occurred during the rainy season
among the boys enrolled in the trial of VAS versus OPVand affected primarily those who had received VAS. The
effect of VAS versus OPV differed significantly between
the dry and the rainy season with a 10-fold higher mortal-
ity in the rainy season. VAS recipients had a significantly
poorer growth measured by weight and MUAC up to
3 months after enrolment.
Strengths and weaknesses
The close follow up of LBW children has been conducted
since 2002 by the same staff. The trial had to be stopped
prematurely due to the cluster of deaths and the study
therefore did not reach the anticipated sample size.
Mortality
A sudden increase in deaths among boys who had received
VAS in the rainy season provoked our attention and the
decision to halt inclusion. We subsequently detected that
these boys had all been at the neonatal nursery within the
same week. The deaths were mainly due to respiratory
problems. Overall the study sample size was clearly too
small to make firm conclusions on the effect of receiving
VAS versus placebo, but it is noteworthy that there were a
quite strong interaction between VAS and season, with a
tendency for a beneficial effect in the dry season, but a sig-
nificant negative effect in the rainy season.
Growth
We found worse growth for the VAS recipients than the
OPV recipients in the first months of life irrespective of
season. We have studied the effect of neonatal VAS given
with BCG at birth and found a beneficial effect on growth
for boys [19]. Also, a trial from Indonesia showed a benefi-
cial overall effect of neonatal VAS on growth up to 3 years
of age [20]. Another trial from Java, Indonesia, found
complex interactions between VAS and season in children
aged 6–48 months at supplementation with the least
beneficial effect of VAS in seasons with a high burden of
Figure 2 Cumulative mortality curves as a function of receiving
VAS or OPV. (a) Overall, (b) Dry season, (c) Rainy season.
Table 3 The fraction of dead/enrolled children by place of
enrolment, month of enrolment, and randomisation group




ward or health centres
Month of enrolment VAS OPV VAS OPV
February 0/0 (0) 1/2 (50) 0/4 (0) 1/4 (25)
March 2/3 (67) 0/4 (0) 0/11 (0) 1/10 (10)
April 2/6 (33) 1/4 (25) 0/8 (0) 1/10 (10)
May 0/5 (0) 3/4 (75) 1/9 (11) 1/7 (14)
Total, dry season 4/14 (29) 5/14 (36) 1/32 (3) 4/31 (13)
June 0/2 (0) 0/4 (0) 0/5 (0) 0/6 (0)
July 1/3 (33) 0/1 (0) 1/6 (17) 0/8 (0)
August 1/2 (50) 0/2 (0) 0/8 (0) 0/5 (0)
September 5/6 (83) 1/6 (17) 1/9 (11) 0/9 (0)
October 0/4 (0) 0/0 (0) 0/17 (0) 0/20 (0)
November 0/0 (0) 0/3 (0) 0/8 (0) 0/7 (0)
Total, rainy season 7/17 (41) 1/16 (6) 2/53 (4) 0/55 (0)
Total 11/31 (35) 6/30 (20) 3/85 (4) 4/86 (5)





VAS OPV VAS OPV
Resp. diseases 5 1 2 1
Diarrhoea 2 0 0 0
Sepsis 1 0 0 1
Kernicterus 0 1 0 0
Chickenpox 0 0 0 1
Unknown* 3 2 1 3
Total 11 4 3 6
*Three families moved before autopsy, and a diagnosis could not be
established in six children.
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The effect of OPV0 on growth has not been studied before.
Chance or cluster
The sudden increase in the number of deaths among
boys who had received VAS and who had been in contact
with the neonatal nursery made us speculate that they had
been infected with a pathogen that either interacted nega-
tively with VAS or was dealt better with by OPV vaccinated
boys. A pathogen could easily have spread among the
children through the suboptimal hygienic conditions. We
could not identify any likely pathogen or immunologicaldifferences between the two groups which could explain
the cluster, but this is perhaps not surprising as the mortal-
ity was no longer elevated at the time when we collected
throat swaps and immunological samples. The pathological
pictures of the dead children were quite different and the
deaths did not occur immediately. Hence, it is unlikely that
the children died of the same infection. However, it may be
speculated that the pathogen weakened the children who
died later, possibly by encounter with a new pathogen.
When we halted the trial we did not know whether
there might be more deaths among children with whom
we had not yet had contact. However, that was not the
case; there were no additional early deaths among the
children recruited in October and November. The prob-
lem apparently had passed. However, we did not restart
the trial. Though this may have been due to a pathogen
Table 5 The effect of VAS/OPV on anthropometric parameters at baseline, 4 weeks, and 6 months after enrolment
Baseline 4 weeks 6 months
VAS OPV Difference#/GMR¤ RR VAS OPV Difference#/GMR¤ RR VAS OPV Difference RR
N = 77 N = 82 (95% CI) (95% CI) N = 63 N = 66 (95% CI) (95% CI) N = 67 N = 73 (95% CI) (95% CI)
Age, days 2 2 32 34 183 183
Length, 44.9 45.2 0.99¤ 48.3 49.5 0.45¤ 63.0 63.6 −0.32
cm* (0.98-1.01) (0.17-1.16) (−1.31;0.67)
LAZ* −3.01 −2.84 −0.17# −3.38 −2.89 −0.28# −2.16 −1.93 −0.13
(−0.54;0.20) (−0.77;0.22) (−0.59;0.34)
Stunted* 85% 72% 1.19 86% 74% 1.12 55% 37% 1.49
(1.00-1.40) (0.94-1.33) (0.98-2.23)
Weight, 2.05 2.13 0.96¤ 2.84 3.10 −0.26# 6.51 6.57 −0.06
kg (0.92-1.01) (−0.46;-0.07) (−0.43;0.31)
WAZ −2.95 −2.73 −0.20# −3.31 −3.00 −0.46# −3.20 −3.06 −0.11
(−0.47;0.08) (−0.88;-0.04) (−0.61;0.39)
Under- 97% 99% 0.99 87% 73% 1.20 48% 29% 1.68
weight (0.94-1.03) (1.01-1.43) (1.04-2.73)
HC, cm 31.0 31.3 −0.27# 35.3 35.6 −0.22# 42.6 42.8 −0.16
(−0.85;0.31) (−0.76;0.32) (−0.72;0.40)
HCAZ −3.11 −2.89 −0.22# −1.86 −1.47 −0.09# −0.55 −0.43 −0.13
(−0.71;0.26) (−0.55;0.37) (−0.58;0.33)
MUAC, 7.7 7.9 0.80¤ 9.4 10.1 −0.50# 13.9 14.1 −0.21
cm (0.63-1.02) (−0.93;-0.07) (−0.65;0.23)
ACAZ - - - - - −0.35 −0.15 −0.19
(−0.62;0.23)
*Length measures are adjusted for being stunted at baseline.
¤Geometric mean ratio (GMR) is provided for non-normally distributed data, #Difference for normally distributed data.
Abbreviations: RR relative risk; LAZ length-for-age z-score; WAZ weight-for-age z-score; HC head circumference; HCAZ head circumference-for-age z-score; MUAC middle upper arm circumference; ACAZ Arm
circumference-for-age z-score.
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that the same might happen again. Furthermore, the boys
who had received OPV0 clearly grew better in the first
months of life than the boys who had received neonatal
VAS. Hence, there was no indication that it was relevant
to continue the trial.
With the study design it cannot be determined
whether vitamin A was harmful or whether OPV stim-
ulated a non-specific immune response which pro-
vided some protection against infections as also seen
for other live vaccines [22].
When we initiated the trial, all available data suggested
that neonatal VAS be beneficial for boys. However, subse-
quently data from Zimbabwe have been published, showing
a 19% increase in mortality for boys [23]. Though the
results are not directly comparable with the other trials
because the trial was 2-by-2 factorial with provision of
maternal VAS as well, and because the prevalence of HIV
was very high and most deaths occurred in children of
HIV positive mothers, the results nonetheless show that
neonatal VAS can be harmful to boys under certain cir-
cumstances. We have previously found strong seasonal
differences in the response to neonatal VAS [1]. In boys
VAS had a strong beneficial effect in the dry season
(0.45 (0.24 – 0.84)) but tended to have a negative effect
in the rainy season 1.53 (0.84 – 2.79). This could be seen
as support of a negative effect of VAS also in the present
study, though it should be noted that no negative effect
was seen in our other studies [2,24]. Hence we cannot
rule out that neonatal VAS had a negative effect for boys
in the present trial.
However, we are more inclined to believe that OPV0
was particularly beneficial. Though we have previously
found increased male mortality after OPV0, it was based
on an observational study and it is contradicted by other
studies on OPV [25,26]. Observations from Chile and
Brazil showed significant reduction in infantile diar-
rhoea mortality following the first massive vaccination
campaigns with OPV [27,28]. A recent study from
Finland found that children who had received OPV
had fewer episodes of otitis media at age 6–18 months
than control children who received inactivated polio
vaccine (IPV) [29].
The growth data support a beneficial effect of OPV0
rather than a negative effect of VAS since the differences
in growth between the two groups gradually disappeared
as more children in both groups got OPV1 scheduled to
be given at 6 weeks of age.
Hence, rather than neonatal VAS being bad, we are
more in favour of the hypothesis that the immunostimu-
lation provided by OPV may have protected the children
in the OPV group against pathogens circulating possibly
by priming a Th1 type immune response, as hypothe-
sised in several studies [30-32].Conclusion
These observations may be important. The introduction
of neonatal VAS is debated [33-39] and WHO has
launched three mega trials of neonatal VAS with more
than 100,000 children to inform global policy. The present
study does not support a policy of providing VAS, but
clearly it cannot be seen as strong evidence against this
policy on its own rights.
Though OPV0 is official policy, many African children
do not receive it [40]; for example, there are often
special rules not to give OPV0 after two weeks of age.
Furthermore, there are long-term plans to replace
OPV with inactivated polio vaccine (IPV) since OPV is as-
sociated with a small risk of developing polio paralysis
[41]. If OPV has beneficial non-specific effects as sug-
gested by this and other studies [25,26,29,42], replacing
OPV with IPV may not have a beneficial effect on overall
survival. For example, we found that among children ran-
domised to IPV as a control vaccine, girls had significantly
higher mortality than the boys [43].
In conclusion, receiving VAS at birth instead of OPV
was not beneficial for the LBW boys in this trial. Growth
in the first few months of life was affected negatively
and there was a tendency for higher mortality during the
first weeks of life which was statistically significant in
the rainy season. With the premature closure of the trial,
however, the trial was clearly underpowered to establish
a causal relation between the intervention and the out-
comes, and the results cannot be generalised. We think it
is most likely that OPV at birth provided a non-specific
immune stimulation that proved beneficial in dealing with
a circulating respiratory pathogen in the rainy season.
However, the results of this study call for extra caution
when testing the effect of NVAS in the future.
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